Statin use and Vital Organ Failure in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study

doi:10.3389/fphar.2019.00889

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 嬰幼兒保育系 > 期刊論文 > Item 310902800/32515

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/32515

標題:	Statin use and Vital Organ Failure in Patients With Asthma-Chronic Obstructive Pulmonary Disease Overlap: A Time-Dependent Population-Based Study
作者:	Yeh, Jun-Jun(葉俊濬) Syue, Shih-Huei Lin, Cheng-Li Hsu, Chung Y. Shae, Zonyin Kao, Chia-Hung
貢獻者:	Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Famiy Med Chia Nan Univ Pharm & Sci, Dept Childhood Educ & Nursery China Med Univ, Coll Med Mei Ho Univ, Dept Nursing China Med Univ Hosp, Management Off Hlth Data China Med Univ, Coll Med, Grad Inst Biomed Sci China Med Univ, Coll Med, Sch Med Asia Univ, Dept Comp Sci & Informat Engn China Med Univ Hosp, Dept Nucl Med Asia Univ, Dept Bioinformat & Med Engn
關鍵字:	asthma-chronic obstructive pulmonary disease overlap (ACO) hepatic failure renal failure heart failure respiratory failure
日期:	2019-08
上傳時間:	2020-07-29 13:48:07 (UTC+8)
出版者:	FRONTIERS MEDIA SA
摘要:	Objective: The effects of statins on the risk of hepatic, renal, respiratory, and heart failure among patients with asthma-chronic obstructive pulmonary disease overlap (ACO) have not been reported. Design: Time-dependent population-based study. Setting: Patient data from 2000 to 2010 were retrieved from the Taiwan National Health Insurance Research Database. Patients: We divided patients with ACO into cohorts of statin use (N = 1,211) and nonuse (N = 7,443). Measurements and Main Results: The cumulative incidence rates of hepatic, renal, respiratory, and heart failure were analyzed through Cox proportional regression analysis with time-dependent variables. After adjustment for multiple confounding factors, including age, sex, comorbidities, and medications [statins, inhaled corticosteroid (ICS), or oral steroid (OS)], the adjusted hazard ratios (aHRs) [95% confidence intervals (CIs)] for hepatic, renal, respiratory, and heart failure were 0.50 (0.40-0.64), 0.49 (0.38-0.64), 0.61 (0.27-2.21), and 0.47 (0.37-0.60), respectively. The aHRs (95% Cls) for statin use with [ICS, OS] for hepatic, renal, and heart failure were [0.36 (0.20-0.66), 0.52 (0.39-0.70)]; [0.82 (0.51-1.34), 0.46 (0.33-0.63)]; and [0.66 (0.40-1.07), 0.48 (0.37-0.64)], respectively. Conclusions: The ACO cohort with statin use exhibited lower risk of hepatic, renal, and heart failure than any other cohort, regardless of age, sex, comorbidities, or ICS or OS use. Regarding the combined use of statins and ICS, the risks of hepatic failure were lower. For the combined use of statins and OS, hepatic, renal, and heart failure were less frequent.
關聯:	Frontiers in Pharmacology, v.10, 889
顯示於類別:	[嬰幼兒保育系] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
10.3389-fphar.2019.00889.pdf		1031Kb	Adobe PDF	358	檢視/開啟
index.html		0Kb	HTML	1316	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....